Marija Dunjic

Dr. Marija Dunjic


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MDMomir Dunjic
Momir Dunjic
STStefano Turini
Stefano Turini
LNLazar Nejkovic
Lazar Nejkovic
NSNenad Sulovic
Nenad Sulovic
SCSasa Cvetkovic
Sasa Cvetkovic
DDDina Dolovac
Dina Dolovac
This study presents a comparative analysis of molecular docking data, focusing on the binding interactions of the natural compounds apigenin and luteolin with the proteins TP-53, pRb, and APOBEC, in comparison to conventional pharmacological ligands. Advanced bioinformatics techniques were employed to evaluate and contrast binding energies, showing that apigenin and luteolin demonstrate significantly higher affinities for TP-53, pRb, and APOBEC, with binding energies of −6.9 kcal/mol and −6.6 kcal/mol, respectively. These values suggest strong potential for therapeutic intervention against HPV-16. Conventional ligands, by comparison, exhibited lower affinities, with energies ranging from −4.5 to −5.5 kcal/mol. Additionally, protein–protein docking simulations were performed to assess the interaction between HPV-16 E6 oncoprotein and tumor suppressors TP-53 and pRb, which revealed high binding energies around −976.7 kcal/mol, indicative of their complex interaction. A conversion formula was applied to translate these protein–protein interaction energies to a comparable scale for non-protein interactions, further underscoring the superior binding potential of apigenin and luteolin. These findings highlight the therapeutic promise of these natural compounds in preventing HPV-16-induced oncogenesis, warranting further experimental validation for clinical applications.

14 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMomir Dunjic
Momir Dunjic
STStefano Turini
Stefano Turini
LNLazar Nejkovic
Lazar Nejkovic
NSNenad Sulovic
Nenad Sulovic
SCSasa Cvetkovic
Sasa Cvetkovic
DDDina Dolovac
Dina Dolovac
This study investigates the use of artificial intelligence (AI) and ethnobotanical knowledge to identify natural compounds with potent antiviral activity against HPV-16. Through molecular docking simulations, we evaluated the binding affinities of various essential oil components, in-cluding Apigenin, against the key antigenic determinants of HPV-16 (E6, E7 oncoproteins, and L1 major capsid protein). Apigenin exhibited strong binding affinities, particularly to E6 Oncopro-tein. To further enhance these findings, we employed an AI-driven reverse engineering approach to predict a natural compound with superior efficacy. The AI identified Luteolin, a flavonoid with additional hydroxyl groups, as a promising candidate. Comparative docking studies demon-strated that Luteolin possesses significantly stronger binding affinities to all three HPV-16 targets, surpassing the efficacy of Apigenin. This work highlights the potential of AI in accelerating the discovery and optimization of natural antiviral agents, providing a powerful tool for pharmaco-logical and ethnopharmacological screenings. Our findings suggest that AI-guided identification of natural compounds can lead to the development of more effective antiviral therapies, warranting further experimental validation and potential synthesis in laboratory settings.

11 August 2026 in Life
Verified
Journal Article
Open access
PDF file
KDKatarina Dunjic
Katarina Dunjic
MDMomir Dunjic
Momir Dunjic
MJMarina Gazdic Jankovic
Marina Gazdic Jankovic
MKMarina Miletic Kovacevic
Marina Miletic Kovacevic
Nikolina KastratovicNikolina Kastratovic
Nikolina Kastratovic
STStefano Turini
Stefano Turini
Background: Previous studies have examined bioactive constituents of Prunus dulcis oil, Pinus sylvestris essential oil, and related phytochemical matrices separately; however, their combined chemical profile, comparator-context molecular-docking landscape, and comparative cellular response in melanoma and non-malignant fibroblast models remain insufficiently characterized. Methods: The analyzed study samples were profiled by GC/MS and GC/FID-based fatty-acid methyl ester analysis. An archived molecular-docking dataset was used to summarize structurally plausible interactions of six formulation-associated markers with eight melanoma-relevant or melanoma-adjacent targets and to present representative three-dimensional complexes. Because complete protocol metadata and co-crystallized-ligand redocking records were unavailable, the computational findings were interpreted descriptively. Neutral-red uptake assays assessed the 24 h viability of B16F10 melanoma cells and MRC-5 fibroblasts after exposure to each oil, the dual-oil formulation, or cisplatin. Four-parameter logistic models provided estimated IC50 values, and exact two-sided permutation tests were used for Spearman rank analyses. Results: The dual-oil formulation yielded estimated IC50 values of 1.42% v/v in B16F10 cells and 4.85% v/v in MRC-5 cells, corresponding to an apparent selectivity index of 3.41. The complete eight-concentration series was non-monotonic and showed no significant rank association (B16F10: ρs = −0.4286, exact p = 0.2992; MRC-5: ρs = −0.3810, exact p = 0.3599). In a post hoc analysis of the descending branch (≥0.37% v/v), the association was perfect in B16F10 cells (ρs = −1.0000, exact p = 0.0167) but did not reach significance in MRC-5 cells (ρs = −0.9000, exact p = 0.0833). The docking matrix identified target-dependent numerical prioritization patterns; however, small score differences were not interpreted as evidence of stronger binding or cellular target engagement. Conclusions: The findings define an exploratory chemical–computational–cellular framework and a preliminary formulation-level viability phenotype. They do not establish synergy, apoptosis, pathway modulation, therapeutic efficacy, or clinical safety. Independent multi-batch chemical confirmation, a fully documented and redocking-validated computational protocol, expanded melanoma and normal-skin cell panels, orthogonal functional assays, longer exposure periods, mechanistic validation, and subsequent in vivo studies are required.

1 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMomir Dunjic
Momir Dunjic
STStefano Turini
Stefano Turini
TNTatjana Novakovic
Tatjana Novakovic
LNLazar Nejkovic
Lazar Nejkovic
JZJing Zhao
Jing Zhao
KDKatarina Dunjic
Katarina Dunjic
Streptococcus pyogenes and Streptococcus agalactiae are major Gram-positive patho-gens implicated in recurrent and invasive genital infections, and the rise of antimicrobial resistance underscores the need for alternative localized therapies. This study combined molecular docking with a prospective pilot clinical evaluation of an essential-oil-based vaginal capsule formulation intended for localized intravaginal administration. Terpinen-4-ol, isoflavone, and secoisolariciresinol diglucoside (SDG) were analyzed against two bacterial targets - the redox-sensing transcriptional repressor Rex from S. agalactiae and the protein tyrosine phosphatase from S. pyogenes - using the 1-Click Docking platform and the Lamarckian Genetic Algorithm. In parallel, 47 women aged 19-27 years were identified with vaginal and/or cervical colonization or infection caused by S. agalactiae or S. pyogenes, and 34 of them entered a prospective pilot treatment study with once-daily vaginal capsules for 7 days; persistent positive cases received an additional 7-day course. Isoflavone and SDG showed the most favorable interactions against the S. agalactiae target, while SDG also displayed comparatively favorable interaction against the S. pyogenes target. In the clinical pilot cohort, microbiological eradication after completion of therapy reached 91.7% for S. agalactiae and 80.0% for S. pyogenes. The parallel trend between stronger in silico prioritization for the S. agalactiae-directed target and higher clinical eradication in the pilot cohort supports a cautious translational hypothesis, but the absence of a control group, the limited sample size, and the exploratory nature of the clinical dataset require restrained interpretation. Overall, these findings support further controlled studies designed to test whether the computationally prioritized phytocompounds contribute to measurable in vivo benefit within localized antimicrobial strategies.

10 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KDKatarina Dunjic
Katarina Dunjic
MDMomir Dunjic
Momir Dunjic
MJMarina Gazdic Jankovic
Marina Gazdic Jankovic
MKMarina Miletic Kovacevic
Marina Miletic Kovacevic
Nikolina KastratovicNikolina Kastratovic
Nikolina Kastratovic
STStefano Turini
Stefano Turini
This study integrates a multi-target in silico screening campaign with in vitro experimental validation to assess a dual-oil phytochemical formulation (cold-pressed Prunus dulcis oil combined with Pinus sylvestris essential oil enriched in α-pinene; commercially referred to as “Naevus Support”) as a candidate adju-vant/alternative strategy against malignant melanoma. First, a comparative molecular docking workflow was applied across a melanoma-relevant target panel spanning the MAPK axis (BRAF, MEK1, ERK2), cell-cycle control (CDK4/6), DNA damage signaling (PARP1), inflammatory lipid signaling (COX-2), and melanogenesis-associated enzymes (tyrosinase), benchmarking major oil constituents and derived chemo-types against standard-of-care inhibitors. Docking energetics and pose-level interaction forensics supported a polypharmacology profile consistent with concurrent suppression of oncogenic signaling nodes and mi-croenvironmental permissive pathways. Second, the same formulation was tested in a Neutral Red Uptake (NRU) viability assay on B16F10 malignant melanoma cells and MRC-5 human fibroblasts, using cisplatin as a reference cytotoxic agent. Across a concentration range of 3–0.045% (v/v) for oils and 20–0.18 mM for cisplatin, the dual-oil formulation induced a dose-dependent reduction of melanoma viability while main-taining comparatively lower toxicity on fibroblasts, indicating a therapeutically relevant selectivity window. Individual-oil profiling suggested that the combined formulation’s anticancer activity cannot be explained by single-oil effects alone, supporting a true inter-oil synergistic enhancement that aligns with the mul-ti-node in silico predictions. Collectively, these data provide a coherent in silico-to-in vitro rationale for further mechanistic follow-up (target deconvolution, pathway readouts, and lipidomic/ROS endpoints) and in vivo translation.

1 January 2025 in Medicinski podmladak
Verified
Journal Article
Open access
PDF file
MDMarija Dunjic
Marija Dunjic
DPDijana Perovic
Dijana Perovic
GSGordana Supic
Gordana Supic
Melanoma, an aggressive skin tumor with a high mortality rate in advanced stages, represents a global health challenge. Genetic alterations play a pivotal role in its onset and progression. Recent studies have established a connection between melanoma and changes in signaling pathways involved in cell cycle regulation, notably the MAPK pathway. Over 80% of melanomas exhibit mutations in BRAF, RAS, and NF1, key genes of this signaling chain. Targeted therapies such as BRAF and MEK inhibitors have been developed. However, frequent secondary resistance to this therapy, as well as the existence of melanoma without these mutations, known as "triple wild type", emphasizes the need for further genetic research and improvement of therapeutic strategies. Mutations in genes like KIT, GNAQ/11, PTEN, and TERT are also associated with melanoma pathogenesis, and some of them with specific subtypes of this tumor. Hereditary predisposition is detected in only 5 - 10% of cases, with CDKN2A and CDK4 identified as the two most common genes in the familial form of melanoma. Exposure to UV radiation has been found as the primary risk factor in shaping the genetic profile of melanoma, leading to the development of "UV signature mutations" that cause further errors in DNA replication and melanomagenesis. Additionally, variations in genes regulating the synthesis of the protective pigment eumelanin during sun exposure, such as MC1R and MITF, pose risks fwor this disease. Studying precursor lesions, such as melanocytic nevi, has contributed to the understanding of melanoma's genetic evolution. Identification of mutations like BRAF V600E in these lesions highlights the role of additional genetic changes in malignant transformation. Future research is expected to identify new genetic markers that would improve understanding, prevention, and diagnosis of melanoma, which will enable a personalized approach to treatment with improved efficiency and reduced side effects of therapy.